Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 619 results
Found 619 results.


McLinden RJ, Paris RM, Polonis VR, et al. "Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)." AIDS. 2012;26(1):1-9.
Kang M, Cu-Uvin S. "Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy." HIV Med.. 2012;13(6):372-8.
Anthony DD, Conry SJ, Medvik K, et al. "Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection." J. Infect. Dis.. 2012;206(6):969-73.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D. "Clinical perspectives on human genetic screening to prevent nevirapine toxicity." Per Med. 2012;9(7):773-782.
Carlson JM, Brumme CJ, Martin E, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." J. Virol.. 2012;86(24):13202-16.
Morris BL, Scott CA, Wilkin TJ, et al. "Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development." HIV Clin Trials. 2012;13(1):1-10.
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Rouabhia M, Semlali A, Chandra J, Mukherjee P, Chmielewski W, Ghannoum MA. "Disruption of the ECM33 gene in Candida albicans prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis." Mediators Inflamm.. 2012;2012:398207.
Wang R, Bosch RJ, Benson CA, Lederman MM. "Drug-resistant virus has reduced ability to induce immune activation." J. Acquir. Immune Defic. Syndr.. 2012;61(4):e60-3.
Campbell TB, Smeaton LM, Kumarasamy N, et al. "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings." PLoS Med.. 2012;9(8):e1001290.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Schouten JThomas, Schiffer JT. "Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;60(1):68-71.
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA. "Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095." J Am Stat Assoc. 2012;107(498):542-554.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Blanchard-Horan C, Stocker V, Moran L, et al. "Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials." Appl Clin Trials. 2012;21(1):34-42.
Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE. "Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients." HIV Clin Trials. 2012;13(2):70-82.
McLaren PJ, Ripke S, Pelak K, et al. "Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans." Hum. Mol. Genet.. 2012;21(19):4334-47.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.
Skinner-Adams TS, Butterworth AS, Porter KA, et al. "The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment." PLoS ONE. 2012;7(4):e34399.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Lorenzana SB, Hughes MD, Grinsztejn B, et al. "Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial." AIDS. 2012;26(9):1083-93.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.